Li et al. demonstrated that radiotherapy downregulated claudin-5 and weakened the BBB, increasing anlotinib distribution in the central nervous system by 1.0–2.9 times when combined with radiotherapy for glioblastoma (Li et al., 2023). This evidence concerns the gene CLDN5 and glioblastoma.